FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193797634> ?p ?o ?g. }

• W3193797634 endingPage "341" @default.
• W3193797634 startingPage "334" @default.
• W3193797634 abstract "Uterine serous carcinoma (USC) is an aggressive histologic variant of endometrial cancer which portends a poor prognosis. DHES0815A is a novel antibody-drug-conjugate (ADC) which binds specifically to HER2 overexpressing tumors at a distinct epitope from that bound by trastuzumab and pertuzumab after which it delivers the toxic payload, PBD-MA, a DNA mono-alkylating agent. The objective of this study was to evaluate the preclinical activity of DHES0815A against primary USC cell lines and xenografts.Twelve primary USC cell lines were assessed by immunohistochemistry (IHC) for HER2 protein expression and for C-erbB2 gene amplification using fluorescent in situ hybridization (FISH) analysis. Cell viability and bystander killing in USC cell lines after exposure to DHES0815A, the non-targeted ADC, and the unconjugated antibody (i.e. MHES0488A) were evaluated using flow cytometry-based-assays. In vivo activity of DHES0815A was tested against HER2/neu overexpressing USC xenografts.High HER2/neu protein expression was seen in 25% (3/12) of the primary USC cell lines. USC cell lines overexpressing HER2/neu were significantly more sensitive to DHES0815A when compared to the non-targeted control ADC (p < 0.001). DHES0815A did not induce significant bystander killing of HER2/neu negative tumors when admixed with HER2/neu positive tumors. DHES0815A caused growth-inhibition and increased survival in USC HER2/neu overexpressing xenografts when compared to controls (p < 0.01).DHES0815A is both highly selective and toxic to USC tumors overexpressing HER2/neu both in vitro and in vivo. HER2-directed ADCs, alone or in combination with other HER2/neu targeted agents may represent a novel treatment option for patients with tumors harboring HER2/neu overexpression refractory to trastuzumab and traditional chemotherapy." @default.
• W3193797634 created "2021-08-30" @default.
• W3193797634 creator A5002030063 @default.
• W3193797634 creator A5002826928 @default.
• W3193797634 creator A5003477055 @default.
• W3193797634 creator A5005598758 @default.
• W3193797634 creator A5010339370 @default.
• W3193797634 creator A5014098371 @default.
• W3193797634 creator A5021257078 @default.
• W3193797634 creator A5024732018 @default.
• W3193797634 creator A5026827320 @default.
• W3193797634 creator A5027337412 @default.
• W3193797634 creator A5032849063 @default.
• W3193797634 creator A5042405282 @default.
• W3193797634 creator A5042993069 @default.
• W3193797634 creator A5046373211 @default.
• W3193797634 creator A5046857977 @default.
• W3193797634 creator A5055849837 @default.
• W3193797634 creator A5061191066 @default.
• W3193797634 creator A5061703014 @default.
• W3193797634 creator A5062471254 @default.
• W3193797634 creator A5064356625 @default.
• W3193797634 creator A5064466179 @default.
• W3193797634 creator A5080849182 @default.
• W3193797634 creator A5084487777 @default.
• W3193797634 creator A5084497328 @default.
• W3193797634 creator A5089407483 @default.
• W3193797634 date "2021-11-01" @default.
• W3193797634 modified "2023-09-26" @default.
• W3193797634 title "DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo" @default.
• W3193797634 cites W1571858787 @default.
• W3193797634 cites W1984007340 @default.
• W3193797634 cites W1984136423 @default.
• W3193797634 cites W1984621921 @default.
• W3193797634 cites W1994381471 @default.
• W3193797634 cites W2005553722 @default.
• W3193797634 cites W2010442254 @default.
• W3193797634 cites W2018152463 @default.
• W3193797634 cites W2044869180 @default.
• W3193797634 cites W2055922116 @default.
• W3193797634 cites W2065949107 @default.
• W3193797634 cites W2078059553 @default.
• W3193797634 cites W2093215461 @default.
• W3193797634 cites W2114282952 @default.
• W3193797634 cites W2116150122 @default.
• W3193797634 cites W2118224996 @default.
• W3193797634 cites W2118510249 @default.
• W3193797634 cites W2120627364 @default.
• W3193797634 cites W2133029659 @default.
• W3193797634 cites W2136527721 @default.
• W3193797634 cites W2137228442 @default.
• W3193797634 cites W2137763083 @default.
• W3193797634 cites W2159967578 @default.
• W3193797634 cites W2166199281 @default.
• W3193797634 cites W2168106779 @default.
• W3193797634 cites W2388163742 @default.
• W3193797634 cites W2416202632 @default.
• W3193797634 cites W2507318226 @default.
• W3193797634 cites W2767025650 @default.
• W3193797634 cites W2767805709 @default.
• W3193797634 cites W2794839527 @default.
• W3193797634 cites W2911188335 @default.
• W3193797634 cites W2996630100 @default.
• W3193797634 cites W2999417355 @default.
• W3193797634 cites W3025735868 @default.
• W3193797634 cites W3037541659 @default.
• W3193797634 cites W3041016811 @default.
• W3193797634 cites W3044642812 @default.
• W3193797634 doi "https://doi.org/10.1016/j.ygyno.2021.08.014" @default.
• W3193797634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34452746" @default.
• W3193797634 hasPublicationYear "2021" @default.
• W3193797634 type Work @default.
• W3193797634 sameAs 3193797634 @default.
• W3193797634 citedByCount "7" @default.
• W3193797634 countsByYear W31937976342021 @default.
• W3193797634 countsByYear W31937976342022 @default.
• W3193797634 countsByYear W31937976342023 @default.
• W3193797634 crossrefType "journal-article" @default.
• W3193797634 hasAuthorship W3193797634A5002030063 @default.
• W3193797634 hasAuthorship W3193797634A5002826928 @default.
• W3193797634 hasAuthorship W3193797634A5003477055 @default.
• W3193797634 hasAuthorship W3193797634A5005598758 @default.
• W3193797634 hasAuthorship W3193797634A5010339370 @default.
• W3193797634 hasAuthorship W3193797634A5014098371 @default.
• W3193797634 hasAuthorship W3193797634A5021257078 @default.
• W3193797634 hasAuthorship W3193797634A5024732018 @default.
• W3193797634 hasAuthorship W3193797634A5026827320 @default.
• W3193797634 hasAuthorship W3193797634A5027337412 @default.
• W3193797634 hasAuthorship W3193797634A5032849063 @default.
• W3193797634 hasAuthorship W3193797634A5042405282 @default.
• W3193797634 hasAuthorship W3193797634A5042993069 @default.
• W3193797634 hasAuthorship W3193797634A5046373211 @default.
• W3193797634 hasAuthorship W3193797634A5046857977 @default.
• W3193797634 hasAuthorship W3193797634A5055849837 @default.
• W3193797634 hasAuthorship W3193797634A5061191066 @default.
• W3193797634 hasAuthorship W3193797634A5061703014 @default.
• W3193797634 hasAuthorship W3193797634A5062471254 @default.
• W3193797634 hasAuthorship W3193797634A5064356625 @default.

• next